As a response to the rapidly spreading of the SARS-CoV-2, the scientific community has been forced to accelerate the development of treatments and vaccines for COVID-19.
From our last update of the COVID-19 page on our website, 1970 clinical studies on COVID-19 were registered to different international and national clinical trial registries worldwide until now.
In particular, among these studies, 79 trials are evaluating the effect of candidate vaccines against the SARS-CoV-2.
News from Italy! The Italian Medicine Agency (AIFA) approved a phase 1 clinical study on the vaccine GRAd-COV2 produced by ReiThera, an Italian biotech company.
GRAd-COV2 is a COVID-19 candidate vaccine based on a novel Gorilla adenoviral vector (GRAd-COV2) encoding the full-length coronavirus spike protein.
The study aims to assess the safety and immunogenicity of the GRAd-COV2 vaccine in healthy volunteers aged 18-55 years and elderly volunteers aged 65-85 years.
The study protocol has been positively evaluated by the Italian National Institute of Health (Istituto Superiore di Sanità – ISS) and obtained the approval from the Ethical Committee.
The study centres will be the National Institute for Infectious Disease “L. Spallanzani” in Rome and the Centro Ricerche Cliniche in Verona.
Once phase 1 data is available, then a phase 2/3 trial will be designed to evaluate the efficacy and safety of the vaccine.
Stay tuned for further updates!